Reimagining Drug-Deliverywith MicrofluidicEngineering
Inventage Lab pioneers microfluidic-based drug-delivery platforms that enable exceptional particle uniformity, precise and tunable release kinetics, and seamless scalability from R&D to full commercial manufacturing. By powering long-acting injectables, high-concentration biologics, and next-generation nucleic-acid delivery, we redefine therapeutic performance and expand the boundaries of pharmaceutical innovation.
CEO's Message
CEO's Message
Inventage Lab was founded with a mission to improve human health and quality of life through innovative drug delivery technologies. Our proprietary microfluidics-based platforms IVL-DrugFluidic®, IVL-BioFluidic™, and IVL-GeneFluidic® are redefining the future of long-acting injectables, high-concentration biologics, and gene and nucleic acid therapeutics. IVL-DrugFluidic® enables precise control of microsphere size and release rate for long-acting formulations; IVL-BioFluidic™ provides stable, high-concentration subcutaneous (SC) delivery solutions that enhance patient comfort and accessibility; and IVL-GeneFluidic® offers scalable, continuous LNP manufacturing for next-generation mRNA and gene therapies. In a rapidly evolving global biopharmaceutical landscape, Inventage Lab continues to grow as a trusted global partner through scientific excellence and reliable collaboration driving patient-centered innovation and new therapeutic paradigms worldwide. We remain committed to contributing beyond technology, creating sustainable value for healthier lives and a better future. Thank you for your continued trust and support.
Chief Executive Officer Inventage Lab Inc.
Ju Hee Kim, Ph.D.
IVL Research Center (IRC)
IVL Research Center (IRC)
IVL Research Center (IRC) is Inventage Lab's integrated research organization dedicated to the R&D of microfluidic-based DDS platform technologies, comprising IVL-DrugFluidic®, IVL-BioFluidic™, and IVL-GeneFluidic®. IRC conducts formulation research spanning long-acting injectables, high-concentration biologics, and gene-based drug delivery, covering the entire research cycle from initial formulation design and release-control optimization to process development and scale-up for mass production. By addressing unmet needs in precise release control and formulation stability that were previously unachievable with conventional manufacturing technologies, and by consistently applying platform technologies from research through production, IRC simultaneously achieves a high degree of quality consistency and scalability toward commercialization.
DDS Manufacturing Site
DDS Manufacturing Site
The QuratisBioplant serves as Inventage Lab's GMP manufacturing base for DDS platform-based clinical products and future commercial products. Core manufacturing equipment for DDS production has already been installed, and the site is being prepared to support GMP manufacturing based on Inventage Lab's proprietary platform technologies. Designed to enable smooth scale-up from clinical supply to future commercial manufacturing, the QuratisBioplant will serve as a key production hub connecting platform development, GMP manufacturing, and commercialization.
